Mesothelioma Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

• News
• Research
• Blogs
• Podcasts
• Video
• Funding
• Alerts
• Clinical Trials
• Forums

Regorafenib With Tislelizumab in Patients With Selected Mismatch Repair-Proficient/Microsatellite Stable Cancers
Conditions:   Anal Squamous Cell Carcinoma;   Colorectal Neoplasms;   Soft Tissue Sarcoma;   Malignant Pleural Mesothelioma;   Small Cell Lung Carcinoma;   Castrate Resistant Prostate Cancer;   Neuroendocrine Carcinoma of Prostate;   Gastroenteropancreatic Neuroendocrine Neoplasm Intervention:   Combination Product: Regorafenib in combination with Tislelizumab Sponsors:   Translational Research in Oncology;   Bayer;   Novartis Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 17, 2022 Category: Research Source Type: clinical trials